Solid Biosciences Inc.
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophi…
Biotechnology
US, Cambridge [HQ]
Strategy & Leadership
Mergers & Acquisitions Beta
M&As
M&A Deals · Breakdown
Solid Biosciences Inc. has no acquisition track records yet.
M&A Deals · History
Solid Biosciences Inc. has no acquisition track records yet.